Clinical trial NCT03539952: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
Official title: CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Wilson Disease
Lead sponsor: Orphalan
Sponsor class: INDUSTRY
First posted: 2018-05-30
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, open-label study with an active standard-of-care comparator (penicillamine)

Detailed description: This is a multicenter, randomized, open label study with an active standard-of-care comparator.

Stable patients who are already considered to be stable on their standard-of-care penicillamine chelation therapy for at least 1 year will enroll in the study and enter a 12-week Penicillamine Baseline Period comprising of 1 month (4 weeks) run-in period followed by a 2 month (8 weeks) evaluation period. During this time all patients will continue to take their current penicillamine under study conditions. At the end of the Penicillamine Baseline Period, patients who fulfill the protocol definition of being adequately controlled and tolerating penicillamine will be randomized in a 1:1 ratio to receive either TETA 4HCl or to continue to receive penicillamine. There is then a 24-week Post-randomization Phase comprising of a 1 month (4 weeks) run-in period for both treatment arms and a 5 month (20 weeks) evaluation period.

Patients who successfully complete the 24-week Post-randomization Phase of the study will have the opportunity to enter an Extension Phase. In the first version of the clinical trial protocol, the intention was to have an 18 month (72 weeks) Extension Phase. During the first 24 weeks of the Extension Phase, subjects would continue receiving their allocated TETA 4HCl or penicillamine (i.e., up to Week 60 of the study). Thereafter all patients were receiving TETA 4HCl for a further 48 weeks (i.e., from Week 60 to Week 108). Study clinic visits occur were scheduled every 6 months in the Extension Phase.

With the final version of the protocol, the Extension Phase stopped at Week 60. Patients who already passed the Week 60 visit were allowed to end the study at the next planned visit.

As a consequece end of treatment varied Week 60 and Week 108

Eligibility criteria: Inclusion Criteria:

1. Patient is able to provide, and has provided, written informed consent
2. Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable, including: For US sites: Authorization for Use and Release of Health Research Study Information and for EU sites: Data Protection Consent
3. Male or female, aged ≥ 18 and ≤ 75 years of age at time of consent
4. Patient has a diagnosis of Wilson's disease, as defined by a prior or current Leipzig score of ≥ 4
5. Patient's Wilson's disease is clinically stable, in the opinion of the investigator, and being treated with penicillamine for at least 1 year (52 weeks) prior to the screening/enrolment visit
6. Patient is on a stable dose and regimen of penicillamine for at least 4 months (16 weeks) prior to the screening/enrolment visit (other prescribed treatments for Wilson's disease not permitted during this study)
7. No anticipated need that patient will require additional pharmacological therapies other than study medication, including prescribed zinc therapy, for the management of copper levels during the study
8. Patient must be willing to maintain stable diet throughout the study, and avoid foods with high copper content, including the Penicillamine Baseline Period
9. Patient considered suitable to receive therapy with both TETA 4HCl and penicillamine administered twice a day
10. Negative central laboratory tests for HIV and viral hepatitis (results will be available after start of run-in period)
11. For female patients of childbearing potential, negative urine pregnancy test (at screening/enrolment visit and prior to randomization)
12. For females of childbearing potential, use of a reliable form of contraceptive
13. Patient is considered as able to complete study requirements and attend the study visits, in the opinion of the investigator

    Additional inclusion criteria following receipt of Screening laboratory results
14. Patient is adequately controlled and tolerating penicillamine therapy as defined by fulfilment of all of the following: a. Serum non-ceruloplasmin bound copper (NCC) level between ≥ 25 and ≤ 150 μg/L\* b. 24-hour urinary copper excretion of between ≥ 100 and ≤ 900 μg/24 hours\* c. Alanine transaminase (ALT) \< 2 times upper limit of normal\* d. No other laboratory or clinical findings that would prevent continuation of maintenance therapy, in the opinion of the investigator

    \* Based on results from screening/enrolment visit samples for which can be taken within ± 7 days of visit. Result should be within the assay limits of quantification for the sample. The ranges in μmol of copper are 0.40 to 2.38 μmol/L for NCC and 1.59 to 14.29 for 24-hour urinary copper excretion (using division by 63 of value in μg per Walshe, 2011). In the event that one or more of the above lab values fall outside the specified range, it can be repeated, including at the Week 4 and Week 8 visits.

    Additional inclusion criteria at Week 12 visit (end of Penicillamine Baseline Period) and prior to randomization
15. Patient is adequately controlled and tolerating penicillamine therapy as defined by fulfilment of all of the following criteria:

    1. Serum non-ceruloplasmin bound copper (NCC) level between ≥ 25 and ≤ 150 μg/L\*
    2. 24-hour urinary copper excretion of between ≥ 100 and ≤ 900 μg/24 hours\*\*
    3. Alanine transaminase (ALT) \< 2 times upper limit of normal\*
    4. No other laboratory or clinical findings that would prevent continuation of maintenance therapy, in the opinion of the investigator

       * Based on lab values from Week 8 visit; \*\* Based on lab value from Week 4 visit as routinely not performed at Week 8 visit, however can also be based on value at Week 8 visit if a repeat (unscheduled) urinary copper excretion was performed at this visit. Result should be within the assay limits of quantification for the sample. The ranges in μmol of copper are 0.40 to 2.38 μmol/L for NCC and 1.59 to 14.29 for 24-hour urinary copper excretion (using division by 63 of value in μg per Walshe, 2011). In the event that one or more of the above lab values fall outside the specified range, it can be repeated. The repeat value(s) must be available prior to randomization at Week 12 and, if within specified range, the patient can continue to randomization. If a patient fails this additional criterion at the end of the Penicillamine Baseline Period, the patient can return to the start of the run-in period i.e. Day 1 (but only once). A negative urinary pregnancy test is also required prior to randomization for females of childbearing potential.

Exclusion Criteria:

1. Patient is in 'de-coppering' phase of treatment for Wilson's disease, in the opinion of the investigator
2. Patient evidence of uncontrolled liver disease, including but not limited to:

   1. Modified Nazer score of \> 4 (result may not be available until after start of run in period since based on lab results\*)
   2. decompensated cirrhosis
   3. acute hemolytic anemia
   4. acute hepatitis
   5. hepatic malignancy
   6. evidence of acute liver failure
3. Cause of patient's liver disease is due to another condition, in the investigator's opinion
4. Patient has severe anemia defined as hemoglobin of ≤ 9 g/dL (result will be available after start of run-in period\*)
5. Patient has experienced a gastrointestinal bleed within 6 months (24 weeks) prior to screening/enrolment visit
6. Patient has renal impairment defined as creatinine clearance of ≤ 30 mL/min (result may not be available until after start of run-in period\*), or patient has nephritis or nephrotic syndrome, in the opinion of the investigator
7. Patient has neurological disease that prevents swallowing of study medication (e.g., requires a nasogastric feeding tube) or requires intensive in-patient medical care
8. Patient is currently taking medication containing trientine for management of Wilson's disease or has taken it within 4 months (16 weeks) of screening/enrolment visit
9. Patient is currently receiving prescribed zinc therapy for management of Wilson's disease or has taken it within 4 months (16 weeks) of screening/enrolment visit
10. Patient is taking any of the following concomitant therapies: gold therapy, antimalarial therapy, cytotoxic drugs, oxyphenbutazone, phenyl butazone
11. Patient has a known intolerance, allergy or sensitivity to penicillamine (that is uncontrolled) or to TETA 4HCl, including any component of the study medication
12. For female patients of childbearing potential, planning a pregnancy during study period or currently nursing
13. For female patients of childbearing potential, unable or unwilling to use a reliable form of contraceptive throughout the study
14. Patient is currently participating in another therapeutic study, or has previously participated in a therapeutic study within 30 days of screening/enrolment visit (or longer, if local requirements specify this)
15. Patient has any condition or in any situation which, in the investigator's opinion, puts the patient at significant risk, could confound study results, or may interfere significantly with the patient's participation in the study

Primary outcomes:
measure: Serum NCC Concentration
timeFrame: Week 36
Secondary outcomes:
measure: 24-hour Urinary Copper Excretion (UCE)
timeFrame: Week 36
measure: Clinical Global Impression of Change (CGIC) Rating Scale
timeFrame: Week 36
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University School of Medicine
state: Connecticut
city: Leuven
country: Belgium
facility: KU Leuven, Department of Clinical and Experimental Medicine
city: Curitiba
country: Brazil
facility: Hospital Nossa Senhora das Graças (HNSG)
city: Fortaleza
country: Brazil
facility: Nucleo de Pesquisa e Desenvolvimento de Medicamentos - Universidade Federal do Ceará - Rodolfo Teófilo
city: São Paulo
country: Brazil
facility: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
city: Aarhus
country: Denmark
facility: Hepato-gastroenterologisk afd
city: Bron
country: France
facility: Hospital mother children
city: Paris
country: France
facility: Centre National de Référence Wilson, Hôpital Lariboisière
city: Heidelberg
country: Germany
facility: Innere Medizin
city: Munich
country: Germany
facility: Poliklinik Hepatologie/Transplantationsambulanz
city: Milan
country: Italy
facility: A.O. San Paolo Milano
city: Padova
country: Italy
facility: DiSCOG Gastroenterology Unit
city: Warsaw
country: Poland
facility: Institute of Psychiatry and Neurology
city: Guildford
country: United Kingdom
facility: University of Surrey, Department of Clinical and Experimental Medicine
state: Surrey
city: Leeds
country: United Kingdom
facility: Leeds Teaching Hospitals NHS Trust
Study officials:
References:
citation: Schilsky ML, Czlonkowska A, Zuin M, Cassiman D, Twardowschy C, Poujois A, Gondim FAA, Denk G, Cury RG, Ott P, Moore J, Ala A, D'Inca R, Couchonnal-Bedoya E, D'Hollander K, Dubois N, Kamlin COF, Weiss KH; CHELATE trial investigators. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1092-1102. doi: 10.1016/S2468-1253(22)00270-9. Epub 2022 Sep 30.